CN105001194A - Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof - Google Patents
Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof Download PDFInfo
- Publication number
- CN105001194A CN105001194A CN201510353600.0A CN201510353600A CN105001194A CN 105001194 A CN105001194 A CN 105001194A CN 201510353600 A CN201510353600 A CN 201510353600A CN 105001194 A CN105001194 A CN 105001194A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- ampk
- aminothiophene
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SBQCHWXASOXEKC-UHFFFAOYSA-N CC(COc1ccc(Cc2c(C)c(C)c(C)c(C)c2C)cc1)O Chemical compound CC(COc1ccc(Cc2c(C)c(C)c(C)c(C)c2C)cc1)O SBQCHWXASOXEKC-UHFFFAOYSA-N 0.000 description 1
- ROFYCOAOJYAJSH-UHFFFAOYSA-N COC1=CCC(CCl)C=C1 Chemical compound COC1=CCC(CCl)C=C1 ROFYCOAOJYAJSH-UHFFFAOYSA-N 0.000 description 1
- BNOAXCLVLPXYJT-QGZVFWFLSA-N C[C@H](COc1cc([N+]([O-])=O)c(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OCC(SCc1ccc[s]1)=S Chemical compound C[C@H](COc1cc([N+]([O-])=O)c(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OCC(SCc1ccc[s]1)=S BNOAXCLVLPXYJT-QGZVFWFLSA-N 0.000 description 1
- OIXAYSMZZSFFRP-QGZVFWFLSA-N C[C@H](COc1ccc(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OC(SCc1ccc[s]1)=S Chemical compound C[C@H](COc1ccc(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OC(SCc1ccc[s]1)=S OIXAYSMZZSFFRP-QGZVFWFLSA-N 0.000 description 1
- GWHJZXXIDMPWGX-UHFFFAOYSA-N Cc1ccc(C)c(C)c1 Chemical compound Cc1ccc(C)c(C)c1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 1
- DSMCBTWDDZMPNE-UHFFFAOYSA-N Cc1ccc(C)c(Cc(cc2)ccc2O)c1C Chemical compound Cc1ccc(C)c(Cc(cc2)ccc2O)c1C DSMCBTWDDZMPNE-UHFFFAOYSA-N 0.000 description 1
- ADBCUJNRRXSCHH-UHFFFAOYSA-N Cc1ccc(C)c(Cc(cc2)ccc2OC)c1C Chemical compound Cc1ccc(C)c(Cc(cc2)ccc2OC)c1C ADBCUJNRRXSCHH-UHFFFAOYSA-N 0.000 description 1
- FUOHKPSBGLXIRL-UHFFFAOYSA-N ClCc1ccc[s]1 Chemical compound ClCc1ccc[s]1 FUOHKPSBGLXIRL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
Abstract
The invention relates to the field of medicines related to diabetes type 2 and specifically to an xanthate AMPK activator containing aminothiophene and hexamethylbenzene structures and a preparation method thereof, and application of the activator in preparation of medicines used for treating diabetes type 2.
Description
Technical field
The present invention relates to the pharmaceutical field of diabetes B treatment.More particularly, the present invention relates to medicative a kind of xanthate class AMPK activator, its preparation method containing aminothiophene and mellitene structure of diabetes B tool, and the purposes in pharmacy.
Background technology
Diabetes are the lysis caused by multi-pathogenesis, have influence on the population in the whole world 6%.Expect 2025, number of patients can double again and reach 300,000,000.The most important clinical pathologic characteristic of diabetes is that plasma glucose (blood sugar) concentration increases.It is the major cause leading diabetogenic various clinical symptom that blood sugar concentration increases.Unsteered hyperglycemia causes many diabetic complications, as increased capillary blood vessel and macrovascular diseases risk, comprises ephrosis, neuropathy, retinopathy, hypertension, cerebral ischemia and coronary heart disease etc.Therefore, the key that blood sugar is treatment and prevent diabetes and complication thereof is reduced.
The protein kinase (AMPK) that AMP (adenylic acid) activates participates in multiple metabolic process as a kind of important protein kinase.AMPK plays master switch effect in the balance of adjuster body energy metabolism.In muscle and liver, the activation of AMPK enhances the picked-up of glucose, fatty acid oxidation and insulin sensitivity, and decreases the generation of glucose, cholesterol and triglyceride level.Therefore, AMPK and signal path thereof are diabetes B active drug action target spots.In fact, the biguanides of widespread use clinically at present, controlling as N1,N1-Dimethylbiguanide, phenformin and buformin is exactly AMPK activator.Wherein N1,N1-Dimethylbiguanide is a current most widely used line antidiabetic medicine clinically, be not only first-selected Remedies for diabetes and also on euglycemia without impact.This shows that AMPK is the keying action target spot of type ii diabetes pharmacological agent.But a severe side effect of this widely used biguanides AMPK activator clinically to cause lactic acidosis at present.Lactic acidosis is a kind of serious metabolism class disease, once occur threat to life.Just because of causing lactic acidosis, the biguanides AMPK activator such as phenformin are terminated clinical application in states such as America and Europes.Although N1,N1-Dimethylbiguanide causes the probability of lactic acidosis, comparatively phenformin is low, but in oral antidiabetic drug, it causes serious toxic side effects and causes dead clinical report number maximum, therefore, research and develop novel, non-biguanides AMPK activator to have and important clinical meaning as the medicine of diabetes.
The invention discloses a kind of xanthate class AMPK activator containing aminothiophene and mellitene structure, this compound can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide a kind of AMPK agonist with the excellent activity of formula I.
Another object of the present invention is to provide the method that preparation has the compound of formula I.
The compound that another object of the present invention is to provide containing formula I is treating the application in diabetes B as effective constituent.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has formula I has following structural formula:
Formula I of the present invention is synthesized by following route:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX
3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS
2reaction, obtains corresponding xanthogenate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, X=Br or Cl.
Formula I of the present invention has AMPK activation, can be used as effective constituent for the preparation of diabetes B medicine.The activity of formula I of the present invention is verified by receptor binding assays.
Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking formula I can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I
A. the synthesis of compound IV-1
Compound II per (1.48g, 10mmol) and compound III-1 (2.01g, 10mmol) are dissolved in the CH of 20mL drying
2cl
2in, stirred at ambient temperature, adds anhydrous AlCl
3(1.33g, 10mmol), then reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid.ESI-MS,m/z＝314([M+H]
+)。
B. the synthesis of compound V-1
Compound IV-1 (1.88g, 6mmol) is dissolved in the CH of 15mL drying
2cl
2in, be cooled to-50 DEG C under nitrogen protection, stir, slowly drip the BCl of 1.0M with syringe
3the CH of (10mL, 10mmol)
2cl
2solution, after dropwising, reaction mixture is warmed up to room temperature gradually, and at room temperature stirs 1 hour, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid.ESI-MS,m/z＝300([M+H]
+)。
The synthesis of C.VI-1
Compound V-1 (1.20g, 4mmol) be dissolved in 10mL THF, stirred at ambient temperature, add NaOH (0.40g, 10mmol), stirred at ambient temperature 30 minutes, then add (R)-propylene oxide (0.29g, 5mmol), gained reaction mixture then temperature rising reflux 12 hours, TLC shows reaction to be completed.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid.ESI-MS,m/z＝358([M+H]
+)。
D. the synthesis of Compound I
Compound VI-1 (0.71g, 2mmol) is dissolved in the THF of 10mL drying, and stirred at ambient temperature adds 60%NaH (0.40g, 10mmol), continues stirring 30 minutes, then adds dry CS
2(0.23g, 3mmol), continue stirring 30 minutes, finally add compound VI I-1 (0.42g, 3mmol), reaction mixture at room temperature stirs 5 hours, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I, white solid.ESI-MS,m/z＝545([M+H]
+)。
the synthesis of embodiment 2 reference compound D-1
For further illustrating the good result of the compounds of this invention, the application describes and is all applicant's invention, not yet disclosed Compound D-1, and its structure is as follows:
Synthetic method is as follows:
A. the synthesis of compound IV-2
Compound II per (1.48g, 10mmol) and compound III-2 (1.57g, 10mmol) are dissolved in the CH of 20mL drying
2cl
2in, stirred at ambient temperature, adds anhydrous AlCl
3(1.33g, 10mmol), then reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-2, white solid.ESI-MS,m/z＝269([M+H]
+)。
B. the synthesis of compound V-2
Compound IV-2 (1.61g, 6mmol) is dissolved in the CH of 15mL drying
2cl
2in, be cooled to-50 DEG C under nitrogen protection, stir, slowly drip the BCl of 1.0M with syringe
3the CH of (10mL, 10mmol)
2cl
2solution, after dropwising, reaction mixture is warmed up to room temperature gradually, and at room temperature stirs 1 hour, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-2, white solid.ESI-MS,m/z＝255([M+H]
+)。
The synthesis of C.VI-2
Compound V-2 (1.02g, 4mmol) be dissolved in 10mL THF, stirred at ambient temperature, add NaOH (0.40g, 10mmol), stirred at ambient temperature 30 minutes, then add (R)-propylene oxide (0.29g, 5mmol), gained reaction mixture then temperature rising reflux 12 hours, TLC shows reaction to be completed.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-2, white solid.ESI-MS,m/z＝313([M+H]
+)。
D. the synthesis of Compound D-1
Compound VI-2 (0.62g, 2mmol) is dissolved in the THF of 10mL drying, and stirred at ambient temperature adds 60%NaH (0.40g, 10mmol), continues stirring 30 minutes, then adds dry CS
2(0.23g, 3mmol), continue stirring 30 minutes, finally add compound VI I-3 (0.40g, 3mmol), reaction mixture at room temperature stirs 5 hours, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound D-1, white solid.ESI-MS,m/z＝485([M+H]
+)。
embodiment 3 Compound ira vitro is to the activation of AMPK
To recombinate AMPK enzyme reactivating with LKBl in vitro before enzyme assay expression in escherichia coli people.Use two kinds of technology for detection AMPK enzymic activitys based on fluorescence (α-screening and Delfia) and (comprise 25mM Tris/HCl damping fluid, pH7.5, Hepes damping fluid containing 100 μMs of ATP/50mM respectively at microwell plate, 25mM Tris/HCl damping fluid, pH7.4, containing 125 μMs of ATP) on synthesis skin substrate (AMARAASAAALARRR, i.e. " AMARAA " skin) and serial dilution activator existence under carry out.By adding AMPK (50-100ng) initiation reaction.After mixing, plank is at room temperature hatched 30 minutes.Enzymic activity is detected to measure the phosphoric acid amount of mixing in AMARAA by using the antibody of anti-phosphorylate serine.Activity represents with the percentage (%) contrasting (Basal activity is expressed as 100).
Test result sees the following form.
As can be seen from upper table result, compound of the present invention has very strong activation to AMPK, can as preparation treatment diabetes B medicine.
Claims (3)
1. there is the compound of general formula I,
2. synthesize the method for compound described in claim 1:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX
3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS
2reaction, obtains corresponding xanthogenate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, X=Br or Cl.
3. the application of compound described in claim 1 in preparation treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353600.0A CN105001194A (en) | 2015-06-24 | 2015-06-24 | Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353600.0A CN105001194A (en) | 2015-06-24 | 2015-06-24 | Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105001194A true CN105001194A (en) | 2015-10-28 |
Family
ID=54374104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510353600.0A Pending CN105001194A (en) | 2015-06-24 | 2015-06-24 | Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105001194A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5330696B1 (en) * | 1970-11-10 | 1978-08-29 | ||
| US5621119A (en) * | 1994-07-22 | 1997-04-15 | Heraeus Kulzer Gmbh & Co., Kg | Di(meth)acrylates having cyclic carbonate groups |
| CN1309126A (en) * | 2000-11-09 | 2001-08-22 | 中国科学院兰州化学物理研究所 | S-(2H-thien-2-yl) methyl alkylxanthogenate |
| US20080306084A1 (en) * | 2007-04-30 | 2008-12-11 | Gruenenthal Gmbh | Substituted Amide Compounds |
| CN101998853A (en) * | 2008-04-11 | 2011-03-30 | 默克专利有限公司 | Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators |
-
2015
- 2015-06-24 CN CN201510353600.0A patent/CN105001194A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5330696B1 (en) * | 1970-11-10 | 1978-08-29 | ||
| US5621119A (en) * | 1994-07-22 | 1997-04-15 | Heraeus Kulzer Gmbh & Co., Kg | Di(meth)acrylates having cyclic carbonate groups |
| CN1309126A (en) * | 2000-11-09 | 2001-08-22 | 中国科学院兰州化学物理研究所 | S-(2H-thien-2-yl) methyl alkylxanthogenate |
| US20080306084A1 (en) * | 2007-04-30 | 2008-12-11 | Gruenenthal Gmbh | Substituted Amide Compounds |
| CN101998853A (en) * | 2008-04-11 | 2011-03-30 | 默克专利有限公司 | Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019001383A1 (en) | N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof | |
| US11021454B2 (en) | Type of aryl benzofuran amidated derivative and medical use thereof | |
| IL280598B2 (en) | 2,6-diamino pyridine compounds | |
| TW200815326A (en) | Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as CPT-inhibitors | |
| CN107162921A (en) | The new Phenoxiacetic acid derivatives of one class, its preparation method and its purposes as medicine | |
| CN105001194A (en) | Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof | |
| CN104945371A (en) | Xanthate ester compound containing nitrile thiophene and with hexamethylbenzene structure and preparation method and application thereof | |
| CN104945372A (en) | Dinitrosalicylic xanthate ester compound with hexamethylbenzene structure and preparation method and application thereof | |
| CN104945369A (en) | Xanthic acid ester compound containing hexamethyl benzene ring and nitrobenzene structures and preparation method and application thereof | |
| CN104945370A (en) | Xanthate compound containing halothiophene and nitrobenzene hexamethylbenzene structure, preparation method and application | |
| CN104910130A (en) | Xanthate compound containing hexamethylbenzene ring and aminobenzene structures as well as preparation method and application thereof | |
| CN104892568A (en) | Xanthate ester compound containing haxamethyl benzene ring and nitrile group benzene structure and preparation method and application of xanthate ester compound | |
| CN104892569A (en) | Terminal-substituted nitrobenzene hexamethylbenzene xanthate compound, preparation method and application | |
| CN105037321A (en) | Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof | |
| CN104945431B (en) | A kind of preparation method of the schiff bases vanadyl complex crystal for having biological activity | |
| CN104910129A (en) | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof | |
| CN105037322A (en) | Xanthate compounds containing hexamethylbenzene ring and alkoxyl benzene structures, as well as preparation methods and application thereof | |
| KR20140097108A (en) | Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs | |
| CN104926757A (en) | Diacyl benzylamine AMPK activator containing alcoxyl phenyl group, and preparation method and purpose of diacyl benzylamine AMPK activator | |
| CN104926756A (en) | Di-acyl benzylamine compound with cyano benzene, method for manufacturing di-acyl benzylamine compound and application thereof | |
| CN104926755A (en) | Nitrobenzene di-acyl benzylamine AMPK (adenosine monophosphate activated protein kinase) activator, method for manufacturing same and application of nitrobenzene di-acyl benzylamine AMPK activator | |
| CN105001181A (en) | Bisacyl benzylamine AMPK activator, and preparation method and application thereof | |
| CN105037296A (en) | AMPK activator containing halogenated-benzene bisamides benzylamine structures, and preparation method and application thereof | |
| CN105237595A (en) | N2-glycosyl-substituted 1,2,3-triazole compound and synthesis method and application thereof | |
| CN104513188A (en) | Cyano pyrrolidine derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |
|
| RJ01 | Rejection of invention patent application after publication |